Medscape: Skin adverse events rare after immunotherapy to treat skin cancers
Medscape highlighted University of Cincinnati research published in JAMA Dermatology that found certain skin adverse events were rare following immunotherapy treatments for certain skin cancers.
"Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors are commonly used drugs for the treatment of various cancers," said Pushkar Aggarwal, MD, corresponding author and medical resident/fellow in UC's College of Medicine. "Having knowledge regarding possible associated skin reactions is vital for clinicians to guide management of the skin reaction and whether an adjustment is needed for the PD-1/PD-L1 inhibitors."
The researchers reviewed adverse event reports for patients treated with PD-1 and PD-L1 treatments between January 2004 and May 2023 to identify whether significant signals exist between PD-1/PD-L1 inhibitors and skin tumors keratoacanthoma and cutaneous squamous cell carcinoma (cSCC).
"For both keratoacanthoma and cSCC, significant signals were found with PD-1/PD-L1 inhibitors," Aggarwal said. But, out of 158,000 cases in the review, the data showed only 43 patients developing keratocanthoma and 83 developing cSCC, which highlights the conditions are "relatively rare adverse events."
Aggarwal said case reports, case-control trials and randomized clinical trials are needed to confirm the results of this study.
Featured photo at top of metastatic melanoma cells. Photo/National Cancer Institute.
Latest UC News
- Spectrum News: How to reduce risks of security camera privacy invasionsIndividuals can take steps to protect themselves from privacy invasions, such as ones that led to a more than $5 million settlement with Ring, an Amazon-owned security company, Spectrum News reported.
- Local media cover $13.5 million gift benefiting ALS research and patient careA historic $13.5 million gift from the estate of Hugh H. Hoffman will revolutionize amyotrophic lateral sclerosis (ALS) at the ALS Multidisciplinary Clinic at the University of Cincinnati Gardner Neuroscience Institute.
- New York Magazine: Does eating chocolate actually trigger migraines?The University of Cincinnati's Vincent Martin was featured in a New York Magazine/The Cut article discussing the lack of solid evidence that chocolate is a migraine trigger.
- UC launches new study of drinking waterThe University of Cincinnati is launching a new investigation at its groundwater observatory to examine the ways toxins from distant sources get into drinking water.
- Enquirer: Salacious testimony of 1929 murder at UC rare books libraryThe Cincinnati Enquirer highlights a rare book found in a University of Cincinnati library that chronicled a high-profile murder trial in 1929.
- UC Law celebrates the graduating class of 2024Information about the UC college of Law graduating class of 2024